Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years. Read on to find out why.If you could flag only one type of medication that's perfectly targeted to the huge U.S. market, it would be weight loss drugs.Obesity is an American problem that's not getting better; according to research published in The Lancet medical journal and cited by U.S. News and World Report, the obesity rate here more than doubled in percentage terms from 1990 to 2022. In the former year, slightly over 21% of U.S. adults were obese. Thirty-two years later, that figure was nearly 44%. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool